16% local currency operating profit growth adjusted for the NNIT divestment
Sales increased by 25% in Danish kroner and by 9% in local currencies to DKK 52.3 billion.
Sales of Victoza® increased by 41% (22% in local currencies).
Sales of Levemir® increased by 28% (10% in local currencies).
Sales in North America increased by 35% (10% in local currencies).
Sales in International Operations increased by 26% (17% in local currencies).
Sales in Region China increased by 25% (3% in local currencies).
Gross margin improved by 2.2 percentage points in Danish kroner to 85.2% driven by a positive currency impact and product mix.
Operating profit increased by 57% in Danish kroner and by 30% in local currencies to DKK 26.3 billion. Adjusted for the DKK 2.4 billion non-recurring income related to the partial divestment of NNIT, operating profit in local currencies increased by 16%.
Net profit increased by 35% to DKK 18.2 billion. Diluted earnings per share increased by 38% to DKK 7.02. Adjusted for the partial divestment of NNIT, net profit and diluted earnings per share increased by 20% and 22% respectively.
In July, Novo Nordisk announced the successful completion of the first phase 3a trial with semaglutide, a new GLP-1 analogue to be administered subcutaneously once weekly.
Novo Nordisk successfully completed the first phase 3a trial with liraglutide as adjunct therapy to insulin for people with type 1 diabetes, in July.
For 2015, sales growth measured in local currencies is still expected to be 7-9%, whereas operating profit growth measured in local currencies is raised by two percentage points and now expected to be around 19%.
Lars Rebien Sørensen, President and CEO: "We are satisfied with the results of the first six months of 2015, during which Victoza® and Levemir® continued to drive sales growth. In the second quarter, we have successfully launched NovoEight® and Saxenda® in the US and announced positive results from the first phase 3a trial for semaglutide, our once-weekly GLP-1 analogue."
Contacts for further information